WuXi XDC Cayman Inc. (2268.HK), a Shanghai-based CRDMO specializing in bioconjugates, and US-based Earendil Labs, an AI-driven biotechnology company, have entered a strategic collaboration centered on WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform. Under the agreement, Earendil Labs receives an exclusive global license to the WuXiTecan-2 payload-linker for use against multiple specific targets, with the total potential deal value reaching up to approximately USD 885 million.
The deal encompasses an upfront payment alongside development, regulatory, and sales milestone payments, with specifics not disclosed. WuXi XDC will also be eligible to receive tiered royalties on net sales upon commercialization of any resulting antibody-drug conjugate (ADC) products.
The collaboration sees WuXi XDC providing its integrated CRDMO platform to support all Chemical, Manufacturing, and Controls development and manufacturing of the ADC components generated under the partnership. This covers antibody intermediates, chemical payloads and linkers, bioconjugate drug substances, and drug products.
Earendil will be responsible for subsequent product development, global regulatory submissions, and commercialization of the resulting candidates. The company plans to conjugate antibodies and bispecific antibodies discovered through its proprietary AI platform with the WuXiTecan-2 payload-linker to advance ADC candidates against the specified targets.
WuXi XDC has positioned itself as both a technology licensor and a contract manufacturer in the ADC space, creating a dual revenue stream from partners who license its conjugation chemistry and then engage its manufacturing infrastructure for GMP production.
The WuXiTecan-2 payload-linker belongs to the topoisomerase I inhibitor class, part of the camptothecin/exatecan derivative family that has become central to contemporary ADC design. This payload class has gained considerable traction following the clinical performance of marketed antibody-drug conjugates ADC products such as Enhertu (trastuzumab deruxtecan), developed by Daiichi Sankyo and AstraZeneca, which demonstrated activity across multiple tumor types including HER2-low breast cancer.
Earendil Labs brings an AI-powered antibody discovery and optimization platform capable of generating monoclonal antibodies and bispecific or multi-specific antibodies. The company and its affiliate Helixon Therapeutics use machine learning, generative protein engineering, and high-throughput experimental techniques to optimize functionality, manufacturability, and developability of protein-based biologics.
Separately, Earendil Labs has initiated a Phase I study of HXN-1001, a half-life extended anti-TL1A antibody in healthy volunteers, indicating the company has begun generating clinical-stage assets from its AI platform, though this program is unrelated to the ADC collaboration.
